Main Article Content

Khadeeja Khan
Dr Eman Shaukat
Sarwat Jahan
Dr Ambreen Nawaz
Dr Maryam Raza
Dr Rao Salman Aziz
Dr Amal Shaukat
Faiqa Chaudhry
Kanza Saleem




Introduction: Pancreatic carcinoma remains one of the most challenging malignancies to treat, characterized by its aggressive nature and limited response to conventional therapies.

Objective: The main objective of the study is to find the role of ROS and antioxidant biomarkers after chemotherapy in pancreatic carcinoma and its comparison with pharmacotherapy. Methodology of the study: This prospective observational study was conducted at Rashid Latif Medical College, Lahore during June 2022 to June 2023. A total of 220 adult patients diagnosed with pancreatic carcinoma were included in the study. Demographic and clinical data, including age, gender, tumor stage, histological subtype, treatment regimen, and treatment history, were collected from medical records. Baseline laboratory assessments, such as complete blood count, liver function tests, and serum tumor markers, were also recorded.

Results: Among the 220 patients enrolled in the study and the mean age was 56.76 ± 8.01 years. The most common histological subtype was adenocarcinoma (85%), and the majority of patients presented with advanced-stage disease (stage III/IV, 75%). The most frequently administered chemotherapy regimen was gemcitabine-based (65%), followed by FOLFIRINOX (25%) and nab-paclitaxel plus gemcitabine (10%). There were slight increases in Superoxide Dismutase (SOD) and Catalase levels after pharmacotherapy compared to chemotherapy (SOD: 115 ± 14 U/mg protein vs. 110 ± 12 U/mg protein, p = 0.07; Catalase: 90 ± 11 U/mg protein vs. 85 ± 10 U/mg protein, p = 0.04), the differences were not statistically significant. However, Glutathione levels were significantly higher after pharmacotherapy compared to chemotherapy (2.5 ± 0.7 µmol/g Hb vs. 2.2 ± 0.6 µmol/g Hb, p = 0.05). Vitamin C levels showed a significant increase after pharmacotherapy compared to chemotherapy (11 ± 1.8 µmol/L vs. 9 ± 1.5 µmol/L, p < 0.01).

Conclusion: It is concluded that monitoring and modulating ROS and antioxidant biomarkers play a crucial role in improving treatment responses and survival outcomes in pancreatic carcinoma patients. Pharmacotherapy, particularly strategies enhancing antioxidant defenses, shows superior efficacy compared to chemotherapy alone.

Abstract 104 | PDF Downloads 24


1. Zhang L, Li J, Zong L, Chen X, Chen K, Jiang Z, Nan L, Li X, Li W, Shan T, Ma Q, Ma Z. Reactive Oxygen Species and Targeted Therapy for Pancreatic Cancer. Oxid Med Cell Longev. 2016;2016:1616781. doi: 10.1155/2016/1616781. Epub 2016 Jan 3. PMID: 26881012; PMCID: PMC4735911.
2. Huang, R., Chen, H., Liang, J., Li, Y., Yang, J., Luo, C., Tang, Y., Ding, Y., Liu, X., Yuan, Q., Yu, H., Ye, Y., Xu, W., & Xie, X. (2021). Dual Role of Reactive Oxygen Species and their Application in Cancer Therapy. Journal of Cancer, 12(18), 5543-5561.
3. Jin F, Wu Z, Hu X, Zhang J, Gao Z, Han X. et al. The PI3K/Akt/GSK-3β/ROS/eIF2B pathway promotes breast cancer growth and metastasis via suppression of NK cell cytotoxicity and tumor cell susceptibility. Cancer biology & medicine. 2019;16:38–54
4. Shao S, Duan W, Xu Q, Li X, Han L, Li W. et al. Curcumin Suppresses Hepatic Stellate Cell-Induced Hepatocarcinoma Angiogenesis and Invasion through Downregulating CTGF. Oxid Med Cell Longev. 2019;2019:8148510.
5. Liu Y, Guo JZ, Liu Y, Wang K, Ding W, Wang H. et al. Nuclear lactate dehydrogenase A senses ROS to produce alpha-hydroxybutyrate for HPV-induced cervical tumor growth. Nat Commun. 2018;9:4429.
6. Sun Y, Lu Y, Saredy J, Wang X, Drummer Iv C, Shao Y. et al. ROS systems are a new integrated network for sensing homeostasis and alarming stresses in organelle metabolic processes. Redox Biol. 2020;37:101696
7. Holmstrom KM, Finkel T. Cellular mechanisms and physiological consequences of redox-dependent signalling. Nat Rev Mol Cell Biol. 2014;15:411–21.
8. Canli O, Nicolas AM, Gupta J, Finkelmeier F, Goncharova O, Pesic M. et al. Myeloid Cell-Derived Reactive Oxygen Species Induce Epithelial Mutagenesis. Cancer Cell. 2017;32:869–83. e5.
9. Zhong LM, Liu ZG, Zhou X, Song SH, Weng GY, Wen Y. et al. Expansion of PMN-myeloid derived suppressor cells and their clinical relevance in patients with oral squamous cell carcinoma. Oral Oncol. 2019;95:157–63.
10. Zhang J, Li H, Wu Q, Chen Y, Deng Y, Yang Z. et al. Tumoral NOX4 recruits M2 tumor-associated macrophages via ROS/PI3K signaling-dependent various cytokine production to promote NSCLC growth. Redox Biol. 2019;22:101116.
11. Kontomanolis EN, Koutras A, Syllaios A, Schizas D, Mastoraki A, Garmpis N. et al. Role of Oncogenes and Tumor-suppressor Genes in Carcinogenesis: A Review. Anticancer Res. 2020;40:6009–15.
12. Stošić, B., Janković, R., Stošić, M., Marković, D., Veselinović, I., Ilić, I., & Sokolović, D. (2020). Caffeic acid phenethyl ester attenuates changes in pancreatic tissue damage biomarkers induced by cisplatin. Canadian Journal of Physiology and Pharmacology, 98(5), 296-303.
13. Saha, A., Zhao, S., Chen, Z., Georgiou, G., Stone, E., Kidane, D., & DiGiovanni, J. (2021). Combinatorial approaches to enhance DNA damage following enzyme-mediated depletion of L-Cys for treatment of pancreatic cancer. Molecular Therapy, 29(2), 775-787.
14. Yang, Y., Gu, H., Zhang, K., Guo, Z., Wang, X., Wei, Q., ... & Qiu, Z. (2023). Exosomal ACADM sensitizes gemcitabine-resistance through modulating fatty acid metabolism and ferroptosis in pancreatic cancer. BMC cancer, 23(1), 789.
15. Zhou, L., Yang, C., Zhong, W., Wang, Q., Zhang, D., Zhang, J., ... & Xu, M. (2021). Chrysin induces autophagy-dependent ferroptosis to increase chemosensitivity to gemcitabine by targeting CBR1 in pancreatic cancer cells. Biochemical pharmacology, 193, 114813.
16. Luan, M., Feng, Z., Zhu, W., Xing, Y., Ma, X., Zhu, J., ... & Jia, Y. (2024). Mechanism of metal ion-induced cell death in gastrointestinal cancer. Biomedicine & Pharmacotherapy, 174, 116574.
17. Bastani, S., Vahedian, V., Rashidi, M., Mir, A., Mirzaei, S., Alipourfard, I., ... & Akbarzadeh, M. (2022). An evaluation on potential anti-oxidant and anti-inflammatory effects of Crocin. Biomedicine & Pharmacotherapy, 153, 113297.
18. Zhang, Z., Yung, K. K. L., & Ko, J. K. S. (2022). Therapeutic intervention in cancer by isoliquiritigenin from licorice: a natural antioxidant and redox regulator. Antioxidants, 11(7), 1349.

Most read articles by the same author(s)